Skip to main content

Table 1 Summary of the participants stratified by AMD phenotype

From: Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up

  tAMD (n = 24) PCV (n = 30) Total (n = 54) P value
Eye (right eye%) 6 (25%) 13 (43%) 19 (35%) 0.26✝
Gender (males%) 18 (75%) 21 (70%) 39 (72%) 0.92✝
Age, Mean (±SD) (years) 73.2 (±8.5) 76.0 (±7.6) 74.7 (±8.1) 0.21*
Baseline Vision LogMAR (±SD) 0.60 (±0.28) 0.47 (±0.26) 0.53 (±0.28) 0.09*
Baseline macular thickness (±SD) (μm) 392 (±141) 352 (±119) 369 (±129) 0.27*
Baseline GLD (±SD) (μm) 3610 (±962) 4650 (±1665) 4188 (±1480) <0.01*
BMI (±SD) 22.6 (±4.0) 22.1 (±2.8) 22.4 (±3.4) 0.62*
Present or ever-smoking 17 (71%) 20 (67%) 37 (69%) 0.97✝
Hypertension 11 (46%) 13 (43%) 24 (44%) 0.92✝
Diabetic mellitus 5 (21%) 5 (17%) 10 (19%) 0.97✝
Previous PDT therapy     0.40✝
0 16 (67%) 18 (60%) 34 (63%)
1 5 (21%) 4 (13%) 9 (17%)
2 3 (12%) 8 (27%) 11 (20%)
Subretinal hemorrhage (>1DA) 4 (17%) 8 (27%) 12 (22%) 0.58✝
Serous retinal detachment 18 (75%) 26 (87%) 44 (81%) 0.46✝
Macular edema 11 (46%) 12 (40%) 23 (43%) 0.88✝
Retinal pigmented epithelium detachment 21 (88%) 30 (100%) 51 (94%) 0.16✝
Subretinal fibrosis 7 (29%) 4 (13%) 11 (20%) 0.27✝
  1. GLD, Greatest linear dimension; BCVA, Best corrected visual acuity; CRT, Central retinal thickness; BMI, Body mass index; * unpaired t-test ✝ Chi-square test.